Literature DB >> 31083052

Moderators of Response to Cognitive Behavior Therapy for Major Depression in Patients With Heart Failure.

Stephen F Smagula1, Kenneth E Freedland, Brian C Steinmeyer, Meredith J Wallace, Robert M Carney, Michael W Rich.   

Abstract

OBJECTIVE: Although cognitive behavior therapy (CBT) is efficacious for major depression in patients with heart failure (HF), approximately half of patients do not remit after CBT. To identify treatment moderators that may help guide treatment allocation strategies and serve as new treatment targets, we performed a secondary analysis of a randomized clinical trial. Based on evidence of their prognostic relevance, we evaluated whether clinical and activity characteristics moderate the effects of CBT.
METHODS: Participants were randomized to enhanced usual care (UC) alone or CBT plus enhanced UC. The single-blinded outcomes were 6-month changes in Beck Depression Inventory total scores and remission (defined as a Beck Depression Inventory ≤ 9). Actigraphy was used to assess daily physical activity patterns. We performed analyses to identify the specific activity and clinical moderators of the effects of CBT in 94 adults (mean age = 58, 49% female) with HF and major depressive disorder.
RESULTS: Patients benefited more from CBT (versus UC) if they had the following: more medically severe HF (i.e., a higher New York Heart Association class or a lower left ventricular ejection fraction), more stable activity patterns, wider active periods, and later evening settling times. These individual moderator effects were small (|r| = 0.10-0.21), but combining the moderators yielded a medium moderator effect size (r = 0.38; 95% CI = 0.20-0.52).
CONCLUSIONS: These findings suggest that increasing the cross-daily stability of activity patterns, and prolonging the daily active period, might help increase the efficacy of CBT. Given moderating effects of HF severity measures, research is also needed to clarify and address factors in patients with less severe HF that diminish the efficacy of CBT. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov identifier: NCT01028625.

Entities:  

Mesh:

Year:  2019        PMID: 31083052      PMCID: PMC6919214          DOI: 10.1097/PSY.0000000000000712

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  28 in total

1.  Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial.

Authors:  Christopher M O'Connor; Wei Jiang; Maragatha Kuchibhatla; Susan G Silva; Michael S Cuffe; Dwayne D Callwood; Bosh Zakhary; Wendy Gattis Stough; Rebekka M Arias; Sarah K Rivelli; Ranga Krishnan
Journal:  J Am Coll Cardiol       Date:  2010-08-24       Impact factor: 24.094

2.  Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder.

Authors:  Stephen F Smagula; Meredith L Wallace; Stewart J Anderson; Jordan F Karp; Eric J Lenze; Benoit H Mulsant; Meryl A Butters; Daniel M Blumberger; Breno S Diniz; Francis E Lotrich; Mary Amanda Dew; Charles F Reynolds
Journal:  J Psychiatr Res       Date:  2016-07-07       Impact factor: 4.791

3.  Evaluation of a preliminary physical function item bank supported the expected advantages of the Patient-Reported Outcomes Measurement Information System (PROMIS).

Authors:  M Rose; J B Bjorner; J Becker; J F Fries; J E Ware
Journal:  J Clin Epidemiol       Date:  2008-01       Impact factor: 6.437

4.  Circadian rest-activity rhythms predict future increases in depressive symptoms among community-dwelling older men.

Authors:  Stephen F Smagula; Sonia Ancoli-Israel; Terri Blackwell; Robert Boudreau; Marcia L Stefanick; Misti L Paudel; Katie L Stone; Jane A Cauley
Journal:  Am J Geriatr Psychiatry       Date:  2014-06-26       Impact factor: 4.105

5.  Rest-activity rhythm and sleep characteristics associated with depression symptom severity in strained dementia caregivers.

Authors:  Stephen F Smagula; Robert T Krafty; Briana J Taylor; Lynn M Martire; Richard Schulz; Martica H Hall
Journal:  J Sleep Res       Date:  2017-05-10       Impact factor: 3.981

6.  Depression in hospitalized older patients with congestive heart failure.

Authors:  H G Koenig
Journal:  Gen Hosp Psychiatry       Date:  1998-01       Impact factor: 3.238

7.  Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial.

Authors:  Christiane E Angermann; Götz Gelbrich; Stefan Störk; Hilka Gunold; Frank Edelmann; Rolf Wachter; Heribert Schunkert; Tobias Graf; Ingrid Kindermann; Markus Haass; Stephan Blankenberg; Sabine Pankuweit; Christiane Prettin; Martin Gottwik; Michael Böhm; Hermann Faller; Jürgen Deckert; Georg Ertl
Journal:  JAMA       Date:  2016-06-28       Impact factor: 56.272

8.  A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.

Authors:  Renerio Fraguas; Renata Martinho da Silva Telles; Tânia Correa Toledo Ferraz Alves; Anna Maria Andrei; Jairo Rays; Dan V Iosifescu; Mauricio Wajngarten
Journal:  Contemp Clin Trials       Date:  2009-01-24       Impact factor: 2.226

9.  Physical Activity and Incident Depression: A Meta-Analysis of Prospective Cohort Studies.

Authors:  Felipe B Schuch; Davy Vancampfort; Joseph Firth; Simon Rosenbaum; Philip B Ward; Edson S Silva; Mats Hallgren; Antonio Ponce De Leon; Andrea L Dunn; Andrea C Deslandes; Marcelo P Fleck; Andre F Carvalho; Brendon Stubbs
Journal:  Am J Psychiatry       Date:  2018-04-25       Impact factor: 18.112

10.  Stability and fragmentation of the activity rhythm across the sleep-wake cycle: the importance of age, lifestyle, and mental health.

Authors:  Annemarie I Luik; Lisette A Zuurbier; Albert Hofman; Eus J W Van Someren; Henning Tiemeier
Journal:  Chronobiol Int       Date:  2013-08-23       Impact factor: 2.877

View more
  3 in total

1.  Who benefits most from expectancy effects? A combined neuroimaging and antidepressant trial in depressed older adults.

Authors:  Sigal Zilcha-Mano; Meredith L Wallace; Patrick J Brown; Joel Sneed; Steven P Roose; Bret R Rutherford
Journal:  Transl Psychiatry       Date:  2021-09-15       Impact factor: 7.989

Review 2.  Advances in accelerometry for cardiovascular patients: a systematic review with practical recommendations.

Authors:  Tomas Vetrovsky; Cain C T Clark; Maria Cristina Bisi; Michal Siranec; Ales Linhart; James J Tufano; Michael J Duncan; Jan Belohlavek
Journal:  ESC Heart Fail       Date:  2020-07-03

3.  Extending Behavioral Medicine to Heart Failure With Preserved Ejection Fraction.

Authors:  Kristie M Harris; Jeffrey M Testani; Matthew M Burg
Journal:  Psychosom Med       Date:  2020-04       Impact factor: 3.864

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.